All Immunotherapy articles
-
NewsVaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
-
NewsMayo Clinic strategy restores CAR T targets on aggressive thyroid tumours
Mayo Clinic researchers have shown that approved thyroid cancer drugs can restore a key antigen on aggressive tumour cells, making them visible once more to CAR T cells and improving treatment outcomes in preclinical models.
-
News‘Plug-and-play’ CAR T platform enables post-infusion immune cell reprogramming
City of Hope researchers have developed a modular ‘plug-and-play’ CAR T-cell platform that enables post-infusion reprogramming of engineered immune cells, offering a potential solution to treatment resistance driven by tumour evolution.
-
NewsBCG and immunotherapy combination cuts tuberculosis relapse risk
Combining the BCG vaccine with a B-cell-targeting immunotherapy significantly reduced tuberculosis relapse rates in preclinical models.
-
NewsSalk researchers uncover how interferons switch from anti- to pro-cancer
Researchers at the Salk Institute have identified a cellular pathway through which prolonged interferon exposure triggers mitochondrial dysfunction, PGE2 production and suppression of anti-tumour immunity – offering a potential strategy for overcoming immunotherapy resistance.
-
WebinarWhat it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
-
NewsRegnase-1 deletion boosts CAR T-cell efficacy against paediatric osteosarcoma
St Jude researchers have demonstrated that deleting the Regnase-1 gene from CAR T cells significantly improves tumour control and prevents metastasis in preclinical models of relapsed osteosarcoma, paving the way for an early-phase clinical trial.
-
NewsIL-17 identified as potential immunotherapy biomarker in ovarian cancer
A new study has identified IL-17 as a potential biomarker for immunotherapy response in a small subset of clear cell ovarian cancer cases, offering a possible route to personalised treatment for a disease historically resistant to immune-based therapies.
-
NewsExhausted T cells escape tumours to drive lasting cancer immunity
A preclinical study has identified a subset of exhausted, LAG3-expressing T cells capable of migrating out of tumours to establish long-term immune memory, with potential implications for LAG3-targeting cancer immunotherapies.
-
NewsScientists identify a new vaccine design strategy for stronger HIV immunity
Two preclinical studies published in Science Translational Medicine suggest that the binding strength and structural repetitiveness of vaccine nanoparticles could be a critical design parameter in the long-running effort to generate broadly neutralising antibodies against HIV.
-
ArticleFibroblast barrier linked to immunotherapy resistance in colorectal cancer
Why do some colorectal cancers resist immunotherapy? Analysis of patient tumour samples has identified a population of fibroblasts that could help explain treatment resistance.
-
NewsTissue chips target immunotherapy toxicity prediction without animal models
Researchers at the University of Rochester have developed human cell-based tissue chips designed to predict serious immunotherapy toxicities, including cytokine release syndrome, and have secured entry into the FDA’s ISTAND pilot programme.
-
NewsHow CAR T cells are being engineered to target tumour’s ‘soft spot’
A preclinical study published in Nature Biomedical Engineering describes a synthetic biology approach that converts the physical softness of cancer cells into a targetable signal for CAR-T immunotherapy, potentially addressing a key resistance mechanism in solid tumours.
-
NewsWhat Oblenio’s Phase I trial means for autoimmune drug discovery
Oblenio Bio has dosed the first patients in a Phase 1a trial of LBL-051, a tri-specific T cell engager designed to simultaneously target CD19, BCMA and CD3 and eliminate both B cells and plasma cells in a bid to achieve durable immune reset in refractory autoimmune diseases.
-
NewsHow dendritic cells organise tumour immunity – and why drug developers should take notice
A new study published in Science identifies a specialised dendritic cell subset as the cellular architects behind tertiary lymphoid structures, offering a potential new target for boosting anti-tumour immunity and converting immunologically cold tumours into treatment-responsive ones.
-
NewsNew bispecific T cell engager platform targets ovarian cancer in preclinical studies
Scientists at The Wistar Institute have engineered a DNA-delivered bispecific T cell engager using a ‘knob-into-hole’ antibody platform, demonstrating improved persistence and dual-antigen targeting in preclinical ovarian cancer models.
-
NewsSpatial map reveals hidden complexity of bladder cancer tumours
Researchers at MD Anderson Cancer Center have used spatial transcriptomics to chart the internal architecture of muscle-invasive bladder cancer, revealing that luminal and basal cancer cell programmes coexist within single tumours – a finding with significant implications for treatment stratification.
-
WebinarBuilding better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
-
ArticleSynthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
-
NewsEpilepsy drug sodium valproate could improve vaccine immune responses
A commonly prescribed epilepsy drug has shown striking potential as a vaccine booster in a controlled human trial, more than doubling antibody levels and increasing T cell responses tenfold at a fraction of its standard therapeutic dose.